Solid Neoplasms

Oncology·MeSH: Neoplasms

Prevalence

3358.2 / 100K

Incidence

1547.2 / 100K/yr

6 drugs in development·4 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Olaparib	Merck & Co., Inc. (MRK)
platinum	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 1(1)

Drug	Company
E7389-LF	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(3)

Drug	Company
dazostinag	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
dazostinag	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
platinum	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 6 drugs in development for Solid Neoplasms across 4 companies.

There are 2 clinical trials targeting Solid Neoplasms tracked by BioSniper.

The estimated prevalence of Solid Neoplasms is approximately 3358.2 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.